GlassScriptPhysician profile
Alyssa Dawn Yates
NPI 1871950220
$7,035.30
in general payments reported to CMS, 2019-2025
31 companies · $3,066 in 2025
The $3,066 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $1,083 · 2023: $1,024 · 2024: $1,386 · 2025: $3,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,428 · Education: $48.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,427.63 |
| Education | $48.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,201.78 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $658.95 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $611.29 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $444.54 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $405.75 | 2025 | Voquezna |
| Genzyme Corporation | $364.88 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.44 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $280.72 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $270.87 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $252.72 | 2021-2025 | |
| Novo Nordisk INC | $244.87 | 2024 | Wegovy |
| Pfizer INC. | $150.42 | 2021-2025 | |
| Madrigal Pharmaceuticals | $124.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $89.74 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $80.79 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $71.21 | 2025 | Zenpep, Vowst |
| Celltrion USA INC. | $66.46 | 2024-2025 | Vegzelma, Zymfentra |
| Alnylam Pharmaceuticals INC. | $51.12 | 2023-2024 | Givlaari |
| Amgen INC. | $48.47 | 2022-2025 | Uplizna |
| Ipsen Biopharmaceuticals, INC | $47.09 | 2025 | Iqirvo |
| Organon LLC | $42.09 | 2022-2025 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $37.90 | 2023-2024 | Dificid |
| Tersera Therapeutics LLC | $33.76 | 2023-2025 | Xermelo, Zoladex |
| Daiichi Sankyo INC. | $31.23 | 2021-2022 | |
| Lilly USA, LLC | $28.16 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $18.77 | 2024 | Rebyota |
| Janssen Scientific Affairs, LLC | $18.04 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.98 | 2024 | Monoferric |
| Fresenius Kabi USA, LLC | $16.41 | 2023 | Idacio |
| Sandoz INC. | $13.30 | 2022 | |
| Endogastric Solutions, INC | $11.56 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.